Monotherapy to Prevent DES Thrombosis: The Future of DAPT - Patrick Serruys

↳ This is a section part of Moment: CRT 2017 : DES BIOABSORBABLE & DCB TECHNOLOGIES - DES Thrombosis Restenosis and DAPT Duration

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$20.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Monotherapy to Prevent DES Thrombosis: The Future of DAPT - Patrick Serruys  at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$20.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Learning Objectives

Other Components in this Moment

Overview
DES Thrombosis No Longer An Issue With Second Generation DES - William Wijns
DES Restenosis Endangered Species or Still a Burden in 2017? - Creighton Don
Does Neoatherosclerosis Contribute to Very Late Stent Thrombosis of BMS and DES? - Renu Virmani
EVOLVE Short-DAPT Study Design Considerations and Update - Jeffrey Popma
Pros and Cons for Implanting of the DAPT Score? - Roxana Mehran
Poly Pharmacy Anticoagulation OAC & DAPT - Roxana Mehran
DES in AF: WOEST for All or Tailored Approach? - Michael Rinaldi
Short DAPT: The European Experience - Robert Byrne
Monotherapy to Prevent DES Thrombosis: The Future of DAPT - Patrick Serruys
Optimal Study Design for Short DAPT Study - Mitchell Krucoff
Loading Simple Education